Navigation Links
The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
Date:9/13/2007

Study results outline dabigatran etexilate as potential thromboprophylaxis

therapy for patients undergoing total hip replacement surgery

RIDGEFIELD, Conn., Sept. 13 /PRNewswire/ -- Boehringer Ingelheim today announced that the September 15 issue of The Lancet will publish results from the RE-NOVATE study, which investigated dabigatran etexilate as a potential therapy for patients undergoing total hip replacement surgery(1). The results from this study demonstrate that both doses (220mg and 150mg) of the oral direct thrombin inhibitor, dabigatran etexilate, administered for a median of 33 days, were non-inferior to injectable enoxaparin in reducing the risk of venous thromboembolism (VTE) after total hip replacement surgery with similar safety.

The primary endpoint of this trial was a composite consisting of total venous thromboembolic events and all-cause mortality during treatment, which occurred in 6.0% of the 220mg group and 8.6% of the 150mg group taking dabigatran etexilate, versus 6.7% of the enoxaparin group. Importantly, a pre-specified secondary outcome of major venous thromboembolism and venous thromboembolism-related mortality was also similar between groups, occurring in 3.1% of the 220mg group and 4.3% of the 150mg group taking dabigatran etexilate, versus 3.9% of the enoxaparin group.

Anticoagulation-related bleeding is the primary safety concern during hip replacement surgery, since major bleeding into the replaced joint can have a detrimental impact on clinical outcome(2). Generally, few major bleeding events were reported, occurring at 2.0% in the 220mg group and 1.3% in the 150mg group for dabigatran etexilate, versus 1.6% in the enoxaparin group. Notably about half of all major bleeding events started after surgery and before the first dose of dabigatran etexilate. There were no major bleeding events reported after hospital discharge in the dabigatran etexilate groups.

Data from frequent liver function monitor
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
3. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
4. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
5. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 CytRx Corporation ... development company specializing in oncology, today announced that ... Executive Officer, and David Haen , Vice ... present a corporate overview at two significant investment ... and healthcare industries: the FBR & Co. Second ...
(Date:9/1/2015)... 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... development and sale of broadly enabling, pressure cycling ... life sciences industry, today announced the publication of ... PCT Platform could play a significant role in ... is based on PCT,s unique ability to help ...
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
Breaking Medicine Technology:CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 2CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 3CytRx Announces Participation at FBR & Co. Second Annual Health Conference and Rodman & Renshaw 17th Annual Global Investment Conference 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 2New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 3New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 4New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine 5BerGenBio Appoints Non-Executive Directors 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... Vending Machine,” is still strongly maintaining her firm’s success in the hair care ... In her upcoming city-to-city tour, Ellis will be providing “Look and learn” live ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... real-time monitoring and analysis of pet vital signs and activity, today announced its ... one of the most popular and widely-adopted veterinary hospital Practice Management Software packages ...
(Date:9/1/2015)... New York, New York (PRWEB) , ... September 01, 2015 , ... ... of Zecurion Zlock Mac , its groundbreaking new version of endpoint DLP developed ... testing of Zlock Mac, in which more than 100 IT and information security professionals ...
(Date:9/1/2015)... ... ... SC&H Group, a leading audit, tax, and consulting firm, received multiple honors from ... in the U.S., as well as being ranked a Top 100 Accounting Firm. , ... exclusively on performance in specific areas of financial and operational management. SC&H Group ...
(Date:9/1/2015)... York, NY (PRWEB) , ... September 01, 2015 ... ... that, to date, more than 1,500 investor-families have received permanent green cards (I-829 ... EB-5 projects. , The I-829 petition is the final step of the EB-5 ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2
... of adverse effects of drugs before they are tested ... unexpected effects account for a third of all drug ... the University of California, San Diego (UCSD) have developed ... side effects of pharmaceuticals, and have used the technique ...
... quality of life, researchers say , , TUESDAY, Dec. 11 ... constraint-induced movement therapy, some stroke patients can have significant ... a better quality of life, a new study finds. ... the less-affected hand. This forced them to use their ...
... NEW YORK (Dec. 10, 2007) -- With findings highlighted ... Weill Cornell Medical College in New York City have ... epithelial cells. Epithelial cells line the outside of nearly ... molecular "switch" in developed epithelial cells that selects from ...
... According to survey results released,today, when 2007 ... follow for treating patients with multiple,cardiovascular and metabolic ... they didn,t follow any particular set of guidelines ... queried more than 750 cardiology, endocrinology, nephrology,and primary ...
... the 25 Healthiest Schools in the ... ... Milk,Mustache marketing campaign, in association with the School Nutrition,Association and the President,s ... has been selected as one,of the 25 healthiest schools in the nation. ...
... Amedica Corporation, an,orthopedic implants company focused on ... Food and Drug Administration,has granted a Special 510(k) ... The Valeo VBR spinal implant is intended ... and stabilization of the thoracolumbar spine.,The Valeo VBR ...
Cached Medicine News:Health News:New computational technique can predict drug side effects 2Health News:Stroke Rehab Technique Has Lasting Results 2Health News:Stroke Rehab Technique Has Lasting Results 3Health News:Protein-dependent 'switch' regulates intracellular trafficking in epithelial cells 2Health News:Protein-dependent 'switch' regulates intracellular trafficking in epithelial cells 3Health News:With Obesity, Diabetes, and Cardiovascular Disease on the Rise, Physicians Need More Comprehensive Guidelines 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2
... for patients and health consumers from the ... featured in MedMaster includes why the medication ... potential side effects and warning signs of ... instructions, information on what to do if ...
The mission of AHFS DI Essentials (American Hospital Formulary Service) is to provide an evidence-based foundation for safe and effective drug therapy....
... Injectable Drugs is a dynamic new ... and easy to check on the ... the selected drugs, clear compatibility and ... can quickly take clinical action based ...
... of current natural product information ... with A to Z Drug ... checking. Includes free updates for ... ideal drug reference for physicians, ...
Medicine Products: